Skip to main content

Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022

Written by Customer Service on . Posted in Public Companies.

Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer

IRVINE, Calif., March 28, 2022 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will present new confirmatory data on DetermaIO™, its 27-gene expression test used to identify responders to immune checkpoint inhibitor (ICI) therapies, at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans.

The analysis in the poster builds on previous data, which showed that IO Score correlates with response to Genentech’s Tecentriq® (atezolizumab) ICI therapy for bladder cancer (mUC). The data to be presented at the AACR Annual Meeting 2022 confirm the association of the IO Score with response to ICI treatment in a second, independent, mUC cohort using the same algorithm and threshold previously established and validated in bladder and other tumor types.

Launched for clinical use in Q4 of 2021, DetermaIO has demonstrated the ability to identify responders to ICIs in Lung, TNBC, and Bladder cancers, and across four approved immunotherapies – Keytruda®, Opdivo®, Tecentriq® and Imfinzi® – suggesting a potential pan-cancer and pan-immunotherapy utility in both primary and metastatic settings. Following are details of the data accepted to the AACR Annual Meeting 2022:

  • Title: 1272 / 19 – Confirmatory study of the IO Score, a tumor immune microenvironment (TIME) classifier, demonstrates efficacy in a real-world cohort of metastatic urothelial cancer (mUC) patients treated with immune checkpoint inhibitors (ICIs)
    Session type: PO.CL11.07 – Biomarkers Predictive of Therapeutic Benefit 2
    Authors:  Nielsen, T., et al.
    Date and time: April 11, 2022 | 9:00AM – 12:30PM EST

The abstract is currently available online at the AACR Annual Meeting 2022 website. Oncocyte will be distributing a data press release at 9AM EST on Monday, April 11, summarizing poster results and the implications for DetermaIO.

Oncocyte’s DetermaIO test is a precision diagnostic designed to determine the likelihood of response to immunotherapy and is the first and only test to measure the entire tumor microenvironment (TME). By evaluating the entire TME, the test can help identify patients primed to respond to immunotherapy and patients who may not respond as well, allowing for physicians and their patients to make informed decisions about their treatment journey.

About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI™, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and TheraSure™ are trademarks of Oncocyte Corporation.

Investor Contact

Bob Yedid
LifeSci Advisors, LLC
Tel: 646.597.6989
bob@lifesciadvisors.com

Media Contact

Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
megan.kernan@westwicke.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.